Calithera Biosciences

Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company's lead product candidate in tumor metabolism, CB-839, is an internally discovered, first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism. Calithera is currently evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors.

In tumor immunology, the Company's lead preclinical program is directed at developing inhibitors of the enzyme arginase and may provide a first-in-class therapeutic agent for this novel target. Calithera Biosciences's ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets.

Company Growth (employees)
South San Francisco, US
Size (employees)
50 (est)+14%
Calithera Biosciences was founded in 2010 and is headquartered in South San Francisco, US

Calithera Biosciences Office Locations

Calithera Biosciences has an office in South San Francisco
South San Francisco, US (HQ)
200 343 Oyster Point Blvd

Calithera Biosciences Data and Metrics

Calithera Biosciences Financial Metrics


Net income (FY, 2016)

(38 m)

EBIT (FY, 2016)

(38.3 m)

Market capitalization (21-Jul-2017)

73.1 m

Cash (31-Dec-2016)

10.6 m
Calithera Biosciences's current market capitalization is $73.1 m.
USDFY, 2014FY, 2015FY, 2016

R&D expense

16.4 m23.7 m27.7 m

General and administrative expense

5.4 m9.1 m10.6 m

Operating expense total

21.7 m32.8 m38.3 m


(21.7 m)(32.8 m)(38.3 m)

Interest income

9 k175 k330 k

Net Income

(21.7 m)(32.6 m)(38 m)
USDFY, 2014FY, 2015FY, 2016


102 m6.1 m10.6 m


1.9 m2.6 m1.8 m

Current Assets

103.9 m72.5 m53.6 m


861 k931 k899 k

Total Assets

104.8 m75.8 m54.8 m

Accounts Payable

693 k562 k398 k

Current Liabilities

4.1 m3.8 m4.5 m

Total Liabilities

4.9 m

Additional Paid-in Capital

152.2 m156.4 m172.4 m

Retained Earnings

(51.9 m)(84.5 m)(122.5 m)

Total Equity

100.4 m71.8 m49.9 m

Financial Leverage

1 x1.1 x1.1 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(21.7 m)(32.6 m)(38 m)

Depreciation and Amortization

361 k404 k297 k


(1.5 m)(673 k)787 k

Accounts Payable

543 k(131 k)(28 k)

Cash From Operating Activities

(19.2 m)(29.9 m)(31 m)

Purchases of PP&E

(556 k)(441 k)(401 k)

Cash From Investing Activities

(486 k)(66.8 m)23.7 m

Cash From Financing Activities

87.9 m845 k11.8 m
Y, 2016

Financial Leverage

1.1 x

Calithera Biosciences Operating Metrics

FY, 2016

Phase 1/2


Phase I Trials


Calithera Biosciences Market Value History

Calithera Biosciences Online and Social Media Presence

Calithera Biosciences Company Life and Culture

You may also be interested in